@article{9ef693ced79341cdae07e9ab77ca2eae,
title = "The fossilization of randomized clinical trials",
author = "Paneth, {Nigel S.} and Joyner, {Michael J.} and Arturo Casadevall",
note = "Funding Information: The industry-supported RCTs of mAbs and CCP differed greatly. The mAb trials were conducted rapidly and nearly entirely in outpatients, with resources from Eli Lilly (9–11) and GlaxoSmithKline (12). Two trials principally supported by Regeneron acknowledged some federal support (13, 14). These trials all showed some benefit from mAb treatment. The results of two mAb trials were published, like those of the Pfizer vaccine trial, before the end of 2020, the first year of the pandemic.",
year = "2022",
month = feb,
day = "15",
doi = "10.1172/JCI158499",
language = "English (US)",
volume = "132",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",
}